Research programme - lysosomal storage diseases therapeutics - Vtesse/NCATS

Drug Profile

Research programme - lysosomal storage diseases therapeutics - Vtesse/NCATS

Alternative Names: Cyclodextrin - Vtesse/NCATS; Delta-tocopherol - Vtesse/NCATS; Niemann-Pick disease therapeutics - Vtesse/NCATS; Tocopherol derivatives - Vtesse/NCATS

Latest Information Update: 20 Jan 2015

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer National Center for Advancing Translational Sciences; National Institutes of Health (USA)
  • Class Cyclodextrins; Tocopherols
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Lysosomal storage diseases

Most Recent Events

  • 20 Jan 2015 Early research in Lysosomal storage diseases in USA (unspecified route)
  • 07 Jan 2015 Vtesse establishes CRADA with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences (NCATS) for the development of drugs in Lysosomal storage diseases
  • 07 Jan 2015 Cyclodextrin, delta-tocopherol, and derivatives of tocopherol licensed to Vtesse worldwide for the treatment of Niemann-Pick disease type C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top